Table 1.
Main clinical studies exploiting MSC for therapeutic purposes in RP.
| Disease | Cell Source | Delivery | WHO Identifier | References |
|---|---|---|---|---|
| AMD (GA), RP and ischaemic retinopathy | Autologous BMHSC | Intravitreal injection |
NCT01560715 NCT01518127 NCT01518842 |
[103,104] |
| AMD (GA), RP, RVO and DR | Autologous BMHSC | Intravitreal injection | NCT01736059 | [105] |
| RP | Autologous ADMSC | Subretinal application | Not registered | [128] |
| AMD (GA), RP, OA | Autologous ADMSC And PRP |
Suprachoroidal application | Not registered | [131,132,133,134] |
| RP | Autologous PRP | Subtenon injection | Not registered | [126] |
| RP | Eterologous UC-MSCs | Suprachoroidal application | Ministry of Health 56733164/203 |
[129] |
RP: Retinitis Pigmentosa; AMD: Age related Macular Disease, GA: Geographic Atrophy, OA: Optic Atrophy; DR: Diabetic retinopathy; RVO Retinal Venous Occlusion; BMHSC: Bone Marrow Human Stem Cell; ADMSC: Adipose Derived Mesenchymal Stem Cell; PRP: Platelet Rich Plasma; UC-MSC: Umbilical Cord Mesenchymal Stem Cell.